MedPacto Inc
KOSDAQ:235980
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MedPacto Inc
Common Shares Outstanding
MedPacto Inc
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MedPacto Inc
KOSDAQ:235980
|
Common Shares Outstanding
₩34.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Common Shares Outstanding
₩218.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Common Shares Outstanding
₩20.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Common Shares Outstanding
₩18m
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Common Shares Outstanding
₩53.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Common Shares Outstanding
₩55.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
MedPacto Inc
Glance View
MedPacto, Inc. researches and develops anti-cancer drugs. The company is headquartered in Seoul, Seoul. The company went IPO on 2019-12-19. The firm researches and develops anticancer drugs and diagnostic kits including vactosertib, MA-B2 and others. The products are used as the treatment of multiple myeloma, lung cancer, stomach cancer, colon cancer, blood cancer, triple negative breast cancer and pancreatic cancer, among others.
See Also
What is MedPacto Inc's Common Shares Outstanding?
Common Shares Outstanding
34.3m
KRW
Based on the financial report for Dec 31, 2025, MedPacto Inc's Common Shares Outstanding amounts to 34.3m KRW.
What is MedPacto Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
11%
Over the last year, the Common Shares Outstanding growth was 0%. The average annual Common Shares Outstanding growth rates for MedPacto Inc have been 13% over the past three years , 11% over the past five years .
